Linklaters

Our clients include pharmaceuticals and biotechnology companies, service providers, medical device manufacturers, academic institutions and regulators, all of whom benefit from the experience of our dedicated global, cross practice team, many of which have scientific backgrounds.

 Examples of recent deals include advising:

• Johnson & Johnson on its US$21.3bn acquisition of Synthes Inc., a premier global supplier of orthopaedic devices;
• Wellpoint on the acquisition of CareMore Health Group, Inc;
• Actavis Group and a consortia of stakeholders on the sale of privately owned Actavis to Watson Pharmaceuticals, Inc. for approximately €4.25bn;

• Southern Cross committee of landlords, on the restructuring of Southern Cross care home assets;

• Sanofi on its JV with Merial and Intervet/Schering-Plough (ISP), the animal health business of Schering-Plough;

• Fresenius Medical Care on the establishment of a strategic joint venture with Galenica Ltd. and their subsidiary Vifor Pharma;
• Zydus Cadila (a top five pharmaceutical company in India) in the negotiation of a supply agreement with Abbott Laboratories;
• Apax, Nordic Capital and Capio on the vast majority of Capio’s material transactions around Europe including: the sale of Capio UK and the international aspects, financing and refinancing of the P2P of Unilabs;
• UBS on the Pharmastandard IPO, the first IPO for a Russian pharmaceutical company;

• Fortis on the acquisition of Quality HealthCare Asia Limited.